U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Area of Science:

• Oncology
• Pharmacology
• Regulatory Science

Background:

• Breast cancer treatment has evolved significantly with numerous new drug approvals.
• The period 2010-2020 saw substantial advancements in FDA-approved therapies for breast cancer.

Purpose of the Study:

• To summarize 30 FDA approvals for breast cancer treatments between 2010 and 2020.
• To analyze trial endpoints, results, and regulatory considerations for these approvals.

Main Methods:

• Review of 30 FDA drug approvals for breast cancer from 2010-2020.
• Analysis of trial design, endpoints (progression-free survival, overall survival, objective response rate, pathologic complete response, invasive disease-free survival), and regulatory pathways (regular, accelerated, priority review, Breakthrough Therapy Designation).

Main Results:

• 23 approvals were regular, 7 were accelerated.
• 26 approvals were for metastatic breast cancer (MBC), 4 for early breast cancer.
• Progression-free survival was a key endpoint for MBC approvals (80.8%); pathologic complete response and invasive disease-free survival were used for early breast cancer.
• Many indications benefited from expedited FDA review initiatives.

Conclusions:

• The decade saw significant progress in breast cancer drug approvals, with a focus on metastatic disease.
• FDA initiatives played a crucial role in advancing the development and approval of novel breast cancer therapies.
• Endpoint selection varied based on disease stage, reflecting tailored regulatory approaches.